var data={"title":"Miglustat: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Miglustat: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6584?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=miglustat-patient-drug-information\" class=\"drug drug_patient\">see &quot;Miglustat: Patient drug information&quot;</a> and <a href=\"topic.htm?path=miglustat-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Miglustat: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196682\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zavesca</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855146\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zavesca</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196696\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Enzyme Inhibitor;</li>\n      <li>\n        Glucosylceramide Synthase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196684\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Type 1 Gaucher disease:</b> Oral: 100 mg 3 times daily; dose may be reduced to 100 mg 1 to 2 times daily in patients with adverse effects (ie, tremor, diarrhea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Niemann-Pick Type C disease (off-label use)</b> Oral: 200 mg 3 times daily (Patterson 2007; Santos-Lozano 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12958851\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=miglustat-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Miglustat: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Niemann-Pick Type C disease (off-label use; Patterson 2012):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &lt;12 years: Limited data available. <b>Note:</b> Therapy is recommended for patients with neurological, cognitive, or psychiatric disease manifestations. Doses may be initiated slowly and adjusted for tolerability, particularly GI effects (diarrhea which may require dietary and pharmacologic management); several months of therapy may be necessary to see clinical benefit (eg, 6 to 12 months)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BSA &gt;1.25 m<sup>2</sup>: 200 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BSA &gt;0.88 to 1.25 m<sup>2</sup>: 200 mg 2 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BSA &gt;0.73 to 0.88 m<sup>2</sup>: 100 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BSA &gt;0.47 to 0.73 m<sup>2</sup>: 100 mg 2 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BSA &le;0.47 m<sup>2</sup>: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062617\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196685\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Gaucher disease: </i> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;70 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 50 to 70 mL/minute/1.73 m<sup>2</sup>: 100 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: 100 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Use not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Niemann-Pick Type C disease:</i> (off-label use) (Zavesca Canadian labeling 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 50 to 70 mL/minute/1.73 m<sup>2</sup>: 200 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: 100 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Use not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &lt;12 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 50 to 70 mL/minute/1.73 m<sup>2</sup>: Administer two-thirds of regular dose in 2 equal doses  (adjusted for BSA)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer one-third of regular dose in 2 equal doses (adjusted for BSA)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Not recommended</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20324084\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). However, dosage adjustment unlikely because miglustat is not metabolized by the liver.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196662\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zavesca: 100 mg [contains soybean lecithin]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196649\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196664\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered with or without food; administration between meals may decrease the incidence of diarrhea. Capsules should be taken at the same time each day at regular intervals. If patient is unable to tolerate or swallow capsule whole and  powder is administered, mix powder into a liquid immediately prior to use (do not store); sweetening agents are not expected to interact (data on file [Actelion Pharmaceuticals Ltd, 2011])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196663\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Gaucher disease:</b> Treatment of adult patients with mild-to-moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (eg, due to allergy, hypersensitivity, or poor venous access)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49017210\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Niemann-Pick Type C disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10193844\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zavesca: Brand name for miglustat [U.S., Canada, and multiple international markets], but also brand name for escitalopram [in multiple international markets; ISMP April 21, 2010]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196654\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Percentages reported from open-label, uncontrolled monotherapy trials.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (21% to 22%), dizziness (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (39% to 67%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (89% to 100%), abdominal pain (18% to 67%), flatulence (29% to 50%), nausea (8% to 22%), vomiting (4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (11% to 30%), weakness (17%), leg cramps (4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (&le;17%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Memory impairment (8%), unsteady gait (8%), paresthesia (&le;7%), migraine (&le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Menstrual disease (&le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distension (8%), constipation (8%), xerostomia (8%), anorexia (&le;7%), dyspepsia (&le;7%), bloating (&le;6%), epigastric pain (&le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (6% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (8%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196667\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Hypersensitivity to miglustat or any component of the formulation; women who are or may become pregnant</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196652\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diarrhea: Observed in the majority of patients, many also reported weight loss (within first 12 months of treatment). Diarrhea decreased over time with continued treatment, and may respond to diet modification (eg, reduction of sucrose, lactose and other carbohydrate intake), taking miglustat between meals, and/or to anti-diarrheal medications. If diarrhea occurs during treatment, instruct patients to avoid foods with high carbohydrate content. If symptoms persist, evaluate patients for underlying GI disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral neuropathy: Peripheral neuropathy has been reported; neurologic monitoring is required. Weigh risk versus benefit of therapy if patient develops symptoms (eg, numbness and tingling); treatment discontinuation may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Platelet counts decreased: Mild decrease in platelet counts (without bleeding) has been observed in patients with type 1 Gaucher disease switched from enzyme replacement therapy; monitor platelet counts during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tremor: New-onset or exacerbations of existing tremor may occur. Tremor typically begins within the first month of treatment and may resolve over time (1-3 months) or respond to dosage reduction. Treatment discontinuation may be necessary if tremor does not respond within days of dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustments recommended. Not recommended in patients with severe impairment.</p>\n    <p style=\"text-indent:0em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: Should be administered under the supervision of a physician experienced in treatment of Gaucher disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Registry: A registry has been established and all patients with Gaucher disease, and physicians who treat Gaucher disease are encouraged to participate. Information on the International Collaborative Gaucher Group (ICGG) Gaucher Registry may be obtained at https://www.registrynxt.com or by calling 1-888-404-4413.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299712\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6221699\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10244&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196678\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases the rate, but not the extent, of absorption. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196658\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196668\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. In addition, adverse effects on spermatogenesis and reduced fertility were observed in male animal studies; however, no effect on sperm was observed in healthy male patients. Uncontrolled type 1 Gaucher disease is associated an increased risk of spontaneous abortion; maternal hepatosplenomegaly and thrombocytopenia may also occur and lead to adverse pregnancy outcomes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20616340\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if miglustat is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196669\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Patients with diarrhea should avoid foods with high carbohydrate content.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196660\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Neurologic evaluations baseline and repeated every 6 months; adverse effects; weight; platelet count; renal function</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196651\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Miglustat competitively and reversibly inhibits the enzyme needed to produce glycosphingolipids and decreases the rate of glycosphingolipid glucosylceramide formation. Glucosylceramide accumulates in type 1 Gaucher disease, causing complications specific to this disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196666\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 83-105 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: No binding to plasma proteins</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: No evidence of metabolism in humans</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 97% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 6-7 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 2-2.5 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323414\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Zavesca Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (18): $6,436.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196670\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Brazaves (JP);</li>\n      <li>Zavesca (AT, AU, BB, BE, BG, BR, CH, CL, CO, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HN, HR, HU, IE, IL, IT, KR, LT, LU, MT, NL, NO, NZ, PL, PT, RO, RU, SE, SI, SK, TR, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22572546\"></a>Patterson MC, Hendriksz CJ, Walterfang M, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: An update. <i>Mol Genet Metab</i>. 2012;106(3):330-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglustat-drug-information/abstract-text/22572546/pubmed\" target=\"_blank\" id=\"22572546\">22572546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17689147\"></a>Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann-Pick C disease: a randomized controlled study. <i>Lancet Neurol</i>. 2007;6(9):765-772.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglustat-drug-information/abstract-text/17689147/pubmed\" target=\"_blank\" id=\"17689147\">17689147</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santos-Lozano A, Villamandos GD, Sanchis-Gomar F, et al. Niemann-Pick disease treatment: a systematic review of clinical trials. <i>Ann Transl Med</i>. 2015;3(22):360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/miglustat-drug-information/abstract-text/26807415/pubmed\" target=\"_blank\" id=\"26807415\">26807415</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zavesca (miglustat) [prescribing information]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zavesca (miglustat) [product monograph]. Laval, Quebec, Canada: Actelion; July 2012.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10244 Version 101.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F196682\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F855146\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F196696\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F196684\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F12958851\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062617\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F196685\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20324084\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F196662\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F196649\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F196664\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F196663\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F49017210\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F10193844\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F196654\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F196667\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F196652\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299712\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6221699\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F196678\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F196658\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F196668\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20616340\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F196669\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F196660\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F196651\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F196666\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323414\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F196670\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10244|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=miglustat-patient-drug-information\" class=\"drug drug_patient\">Miglustat: Patient drug information</a></li><li><a href=\"topic.htm?path=miglustat-pediatric-drug-information\" class=\"drug drug_pediatric\">Miglustat: Pediatric drug information</a></li></ul></div></div>","javascript":null}